Details for Patent: 9,795,604
✉ Email this page to a colleague
Which drugs does patent 9,795,604 protect, and when does it expire?
Patent 9,795,604 protects IMBRUVICA and is included in three NDAs.
Protection for IMBRUVICA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has thirty-five patent family members in fourteen countries.
Summary for Patent: 9,795,604
| Title: | Methods of treating and preventing graft versus host disease |
| Abstract: | Described herein are methods for treating and preventing graft versus host disease using ACK inhibitors. The methods include administering to an individual in need thereof an ACK inhibitor such as ibrutinib for treating and preventing graft versus host disease. |
| Inventor(s): | Byrd; John C. (Columbus, OH), Dubovsky; Jason A. (Columbus, OH), Muthusamy; Natarajan (Galloway, OH), Johnson; Amy Jo (Dublin, OH), Miklos; David (Stanford, CA) |
| Assignee: | Pharmacyclics LLC (Sunnyvale, CA) |
| Application Number: | 14/523,650 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 9,795,604 |
|
Patent Claim Types: see list of patent claims | Use; Delivery; |
More… ↓ |
Drugs Protected by US Patent 9,795,604
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharmacyclics Llc | IMBRUVICA | ibrutinib | CAPSULE;ORAL | 205552-002 | Dec 20, 2017 | RX | Yes | No | 9,795,604*PED | ⤷ Subscribe | Y | ⤷ Subscribe | ||||
| Pharmacyclics Llc | IMBRUVICA | ibrutinib | CAPSULE;ORAL | 205552-001 | Nov 13, 2013 | RX | Yes | Yes | 9,795,604*PED | ⤷ Subscribe | Y | ⤷ Subscribe | ||||
| Pharmacyclics Llc | IMBRUVICA | ibrutinib | SUSPENSION;ORAL | 217003-001 | Aug 24, 2022 | RX | Yes | Yes | 9,795,604*PED | ⤷ Subscribe | Y | ⤷ Subscribe | ||||
| Pharmacyclics Llc | IMBRUVICA | ibrutinib | TABLET;ORAL | 210563-001 | Feb 16, 2018 | RX | Yes | No | 9,795,604*PED | ⤷ Subscribe | Y | ⤷ Subscribe | ||||
| Pharmacyclics Llc | IMBRUVICA | ibrutinib | TABLET;ORAL | 210563-002 | Feb 16, 2018 | RX | Yes | No | 9,795,604*PED | ⤷ Subscribe | Y | ⤷ Subscribe | ||||
| Pharmacyclics Llc | IMBRUVICA | ibrutinib | TABLET;ORAL | 210563-003 | Feb 16, 2018 | RX | Yes | Yes | 9,795,604*PED | ⤷ Subscribe | Y | ⤷ Subscribe | ||||
| Pharmacyclics Llc | IMBRUVICA | ibrutinib | TABLET;ORAL | 210563-004 | Feb 16, 2018 | DISCN | Yes | No | 9,795,604*PED | ⤷ Subscribe | Y | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 9,795,604
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 098208 | ⤷ Subscribe | |||
| Australia | 2014339815 | ⤷ Subscribe | |||
| Australia | 2020204270 | ⤷ Subscribe | |||
| Australia | 2022202686 | ⤷ Subscribe | |||
| Australia | 2023274176 | ⤷ Subscribe | |||
| Canada | 2928721 | ⤷ Subscribe | |||
| Canada | 3103411 | ⤷ Subscribe | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
